BRAF and cancer: Interestingly, our findings indicate that the purified PJ agents (PJ1 and PJ9) can disturb sustained MAPK signaling which plays a major role in the mortality of cancer cells, via targeting of both mutant K-Ras and mutant B-Raf proteins.